530207 — Brawn Biotech Income Statement
0.000.00%
Last trade - 00:00- IN₹55.51m
- IN₹41.13m
- IN₹164.95m
- 10
- 42
- 37
- 16
Annual income statement for Brawn Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2023 March 31st | 2024 March 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IAS | IAS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 222 | 165 |
| Cost of Revenue | ||
| Gross Profit | 30.5 | 21.3 |
| Selling / General / Administrative Expenses | ||
| Depreciation and Amortization | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 226 | 181 |
| Operating Profit | -4.13 | -16.2 |
| Gain / Loss on Sale of Assets | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -4.12 | -15.4 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -8.68 | -12.5 |
| Net Income Before Extraordinary Items | ||
| Net Income | -8.68 | -12.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -8.68 | -12.5 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -2.89 | -4.14 |